Mathieu Gerfaud‐Valentin

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors

The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy

Pulmonary sarcoidosis

Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010

The Pleura

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Atypical Hemolytic Uremic Syndrome: A Meta‐Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens

The clinical spectrum of pulmonary aspergillosis

Overview of the IL‐1 family in innate inflammation and acquired immunity

Global and Multi-National Prevalence of Fungal Diseases—Estimate Precision

Cytokine Storm

Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease

Anakinra for the treatment of adult-onset Still’s disease

Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis

Efficacité de l’éculizumab comme traitement de la microangiopathie thrombotique induite par la gemcitabine : à propos d’un cas

Adult-onset Still's disease

Adult-Onset Still Disease

Geoepidemiology and Immunologic Features of Autoinflammatory Diseases: a Comprehensive Review

Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart

Occupational Hypersensitivity Pneumonitis in a Baker

Données actualisées sur la physiopathologie, les phénotypes et les traitements de la maladie de Still de l’adulte